Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single-Center Retrospective Study From 2016 to 2024

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

JGH Open Pub Date : 2025-02-21 DOI:10.1002/jgh3.70122

Xiangchen Meng, Jiafei Peng, Hongtao Wei

{"title":"Etiology and Clinical Features of Secondary Sclerosing Cholangitis: A Single-Center Retrospective Study From 2016 to 2024","authors":"Xiangchen Meng, Jiafei Peng, Hongtao Wei","doi":"10.1002/jgh3.70122","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Secondary sclerosing cholangitis (SSC) is a rare progressive biliary disease. We aimed to analyze the underlying causes, treatment approaches, and prognosis of SSC in order to enhance awareness of this disease.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective analysis was conducted on patients diagnosed with SSC in a single tertiary center in China between October 2016 and March 2024, focusing on the etiology, treatment modalities, and follow-up outcomes. Clinical outcomes were compared to patients with primary sclerosing cholangitis during the same period.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 21 patients were included in the study, with a median age of 42 (interquartile range 34, 57). The primary causes of SSC included surgical injury (seven cases, 33.3%) and drug-induction (six cases, 28.6%). Eight patients (38.1%) underwent ERCP, six patients (28.6%) received PTCD, and two patients (9.5%) underwent choledochoscopic bile duct dilation or stone extraction.Median follow-up time was 13 (interquartile range 10, 35) months, during which five patients (23.8%) died and five patients (23.8%) underwent liver transplants.Comparison of patients who received biliary decompression interventions and patients who did not revealed no significant difference in prognosis (<i>p</i> = 0.45). The median time of transplant-free survival was 35 months in the SSC group compared with 67 months in the PSC group. A trend toward a worse prognosis was observed in SSC compared to PSC (<i>p</i> = 0.13).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SSC is a complex disease with varied etiologies and poor prognosis, particularly when caused by bile duct surgical trauma. Bile duct decompression like ERCP does not offer long-term survival benefits. SSC exhibited a trend towards a less favorable prognosis compared to PSC.</p>\n </section>\n </div>","PeriodicalId":45861,"journal":{"name":"JGH Open","volume":"9 2","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jgh3.70122","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JGH Open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jgh3.70122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Secondary sclerosing cholangitis (SSC) is a rare progressive biliary disease. We aimed to analyze the underlying causes, treatment approaches, and prognosis of SSC in order to enhance awareness of this disease.

Methods

A retrospective analysis was conducted on patients diagnosed with SSC in a single tertiary center in China between October 2016 and March 2024, focusing on the etiology, treatment modalities, and follow-up outcomes. Clinical outcomes were compared to patients with primary sclerosing cholangitis during the same period.

Results

A total of 21 patients were included in the study, with a median age of 42 (interquartile range 34, 57). The primary causes of SSC included surgical injury (seven cases, 33.3%) and drug-induction (six cases, 28.6%). Eight patients (38.1%) underwent ERCP, six patients (28.6%) received PTCD, and two patients (9.5%) underwent choledochoscopic bile duct dilation or stone extraction.Median follow-up time was 13 (interquartile range 10, 35) months, during which five patients (23.8%) died and five patients (23.8%) underwent liver transplants.Comparison of patients who received biliary decompression interventions and patients who did not revealed no significant difference in prognosis (p = 0.45). The median time of transplant-free survival was 35 months in the SSC group compared with 67 months in the PSC group. A trend toward a worse prognosis was observed in SSC compared to PSC (p = 0.13).

Conclusions

SSC is a complex disease with varied etiologies and poor prognosis, particularly when caused by bile duct surgical trauma. Bile duct decompression like ERCP does not offer long-term survival benefits. SSC exhibited a trend towards a less favorable prognosis compared to PSC.

Abstract Image

查看原文本刊更多论文

继发性硬化性胆管炎的病因及临床特征：2016 - 2024年单中心回顾性研究

目的继发性硬化性胆管炎（SSC）是一种罕见的进行性胆道疾病。我们的目的是分析SSC的病因、治疗方法和预后，以提高对这种疾病的认识。方法回顾性分析2016年10月至2024年3月在中国单一三级中心诊断为SSC的患者，重点分析病因、治疗方式和随访结果。将临床结果与同期原发性硬化性胆管炎患者进行比较。结果共纳入21例患者，中位年龄42岁（四分位数间距34,57）。发生SSC的主要原因为手术损伤（7例，33.3%）和药物诱导（6例，28.6%）。8例（38.1%）行ERCP， 6例（28.6%）行PTCD， 2例（9.5%）行胆道镜胆管扩张或取石术。中位随访时间为13个月（四分位数间距为10 ~ 35），随访期间5例（23.8%）死亡，5例（23.8%）行肝移植。胆道减压干预组与未行胆道减压干预组预后无显著差异（p = 0.45）。SSC组无移植生存的中位时间为35个月，PSC组为67个月。与PSC相比，SSC有更差的预后趋势（p = 0.13）。结论SSC是一种复杂的疾病，病因多样，预后差，尤其是胆管手术创伤所致。像ERCP这样的胆管减压不能提供长期的生存益处。与PSC相比，SSC表现出较差的预后趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊